Bundamedik Tbk PT Cash Flow Conversion Efficiency
Bundamedik Tbk PT cash flow conversion efficiency. Based on the latest financial reports, Bundamedik Tbk PT (BMHS) has a cash flow conversion efficiency ratio of 0.083x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp199.64 Billion ≈ $11.70 Million USD) by net assets (Rp2.39 Trillion ≈ $140.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bundamedik Tbk PT (2018–2025)
Cash flow conversion efficiency of Bundamedik Tbk PT from 2018 to 2025. This chart illustrates how Bundamedik Tbk PT's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bundamedik Tbk PT (BMHS) share price today for real-time trading data and today's change.
Bundamedik Tbk PT Cash Flow Conversion Ratio Explained
Bundamedik Tbk PT cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bundamedik Tbk PT Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bundamedik Tbk PT ranked by their cash flow conversion efficiency. Also see Bundamedik Tbk PT market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vivani Medical Inc.
NASDAQ:VANI
|
-0.318x |
|
My Humble House Hospitality Management Consulting Co Ltd
TW:2739
|
0.458x |
|
Pasofino Gold Limited
V:VEIN
|
0.426x |
|
Markforged Holding Corp
NYSE:MKFG
|
-0.293x |
|
Papaya Growth Opportunity Corp I
NASDAQ:PPYA
|
0.001x |
|
EA Technique M Bhd
KLSE:5259
|
0.067x |
|
NCS Multistage Holdings Inc
NASDAQ:NCSM
|
0.056x |
|
Mitake Information
TWO:8284
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Bundamedik Tbk PT (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bundamedik Tbk PT from 2018 to 2025. Review BMHS cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Rp2.39 Trillion ≈ $140.31 Million |
Rp250.62 Billion ≈ $14.69 Million |
0.105x | +561.56% |
| 2024-12-31 | Rp2.15 Trillion ≈ $125.85 Million |
Rp33.98 Billion ≈ $1.99 Million |
0.016x | -44.64% |
| 2023-12-31 | Rp1.80 Trillion ≈ $105.47 Million |
Rp51.44 Billion ≈ $3.01 Million |
0.029x | -78.24% |
| 2022-12-31 | Rp1.81 Trillion ≈ $105.96 Million |
Rp237.47 Billion ≈ $13.91 Million |
0.131x | -36.61% |
| 2021-12-31 | Rp1.69 Trillion ≈ $98.84 Million |
Rp349.44 Billion ≈ $20.48 Million |
0.207x | +14.24% |
| 2020-12-31 | Rp1.05 Trillion ≈ $61.51 Million |
Rp190.36 Billion ≈ $11.15 Million |
0.181x | +34.54% |
| 2019-12-31 | Rp665.59 Billion ≈ $39.00 Million |
Rp89.72 Billion ≈ $5.26 Million |
0.135x | +63.82% |
| 2018-12-31 | Rp532.23 Billion ≈ $31.19 Million |
Rp43.79 Billion ≈ $2.57 Million |
0.082x | -- |
About Bundamedik Tbk PT
PT Bundamedik Tbk provides health care services in Indonesia. It also engages private hospital and healthcare support service activities; provision of ambulance services; private health education; consultant for reproductive technology services management; management consultant of physiotherapy service; and hotel, and dental clinic services management consulting businesses. It also provides ferti… Read more